These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32134758)

  • 21. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Grygier M; Araszkiewicz A; Lesiak M; Janus M; Kowal J; Skorupski W; Pyda M; Mitkowski P; Grajek S
    Am J Cardiol; 2011 Apr; 107(8):1131-5. PubMed ID: 21310372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
    Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
    Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy.
    Tsao TP; Cheng SM; Cheng CC; Yang SP
    Acta Cardiol; 2009 Apr; 64(2):225-30. PubMed ID: 19476116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization.
    Dall'Ara G; Testa L; Tumscitz C; Mattesini A; Gasparini GL; Grotti S; Bollati M; Tarantino F; Di Mario C; Oreglia JA
    J Invasive Cardiol; 2020 Feb; 32(2):58-63. PubMed ID: 32005785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study.
    Jafari Afshar E; Samimisedeh P; Tayebi A; Shafiabadi Hassani N; Rastad H; Yazdani S
    Ther Adv Cardiovasc Dis; 2023; 17():17539447231154654. PubMed ID: 36852839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.
    Bedjaoui A; Allal K; Lounes MS; Belhadi CE; Mekarnia A; Sediki S; Kara M; Azaza A; Monsuez JJ; Benkhedda S
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):45-51. PubMed ID: 30460974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients.
    Yang L; Mu L; Sun L; Qi F; Guo R
    Minerva Cardioangiol; 2017 Apr; 65(2):111-118. PubMed ID: 27249789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of urapidil on heart function and ventricular systolic synchrony in acute myocardial infarction patients with no-reflow phenomenon after percutaneous coronary intervention].
    Chen JL; Fu XH; Jiang YF; Fan WZ; Gu XS; Liu JJ; Geng W
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 Apr; 20(4):197-9. PubMed ID: 18419949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
    Qi Q; Niu J; Chen T; Yin H; Wang T; Jiang Z
    Med Sci Monit; 2018 May; 24():2767-2776. PubMed ID: 29726480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Wu X; Mintz GS; Xu K; Lansky AJ; Witzenbichler B; Guagliumi G; Brodie B; Kellett MA; Dressler O; Parise H; Mehran R; Stone GW; Maehara A
    JACC Cardiovasc Interv; 2011 May; 4(5):495-502. PubMed ID: 21596321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment-Elevation Myocardial Infarction Patients: Where Do We Stand?
    Bulluck H; Foin N; Tan JW; Low AF; Sezer M; Hausenloy DJ
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28242607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention.
    Youssef AA; Wu CJ; Hang CL; Cheng CI; Yang CH; Chen CJ; Chen YH; Chai HT; Chua S; Yeh KH; Yip HK
    Circ J; 2006 Dec; 70(12):1538-42. PubMed ID: 17127795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration.
    Yetgin T; Uitterdijk A; Te Lintel Hekkert M; Merkus D; Krabbendam-Peters I; van Beusekom HMM; Falotico R; Serruys PW; Manintveld OC; van Geuns RM; Zijlstra F; Duncker DJ
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1990-1999. PubMed ID: 26738671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Abdelaziz HK; Elkilany W; Khalid S; Sabet S; Saad M
    Coron Artery Dis; 2017 Jan; 28(1):11-16. PubMed ID: 27556348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis.
    Zhao S; Qi G; Tian W; Chen L; Sun Y
    J Interv Cardiol; 2014 Aug; 27(4):356-64. PubMed ID: 25041036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of intracoronary injection with xuesaitong in treating post-PCI slow-reflow phenomenon in patients with ST-segment elevation myocardial infarction].
    Gan LJ; Zhang CH; Zhang M
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Apr; 30(4):348-51. PubMed ID: 20669666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial).
    De Luca G; Iorio S; Venegoni L; Marino P
    Am J Cardiol; 2012 Jan; 109(2):202-7. PubMed ID: 22000773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Tasar O; Karabay AK; Oduncu V; Kirma C
    Coron Artery Dis; 2019 Jun; 30(4):270-276. PubMed ID: 31026233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.
    Manolis AS
    Curr Vasc Pharmacol; 2019; 17(2):164-179. PubMed ID: 29298651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.